Core Insights - Suzhou Xingao Tuowei Biotechnology Co., Ltd. has recently completed its Series A financing round, raising nearly 100 million RMB [1] - The company aims to define clinical standards for gene therapy in the field of otology in China, leading the standardization of the industry [1] Company Overview - Suzhou Xingao Tuowei Biotechnology Co., Ltd. was established in 2022 and is located in Suzhou, focusing primarily on research and experimental development [1] - The company has a registered capital of 7.882884 million RMB and completed its Series A financing in 2026 [1] Investment and Intellectual Property - The company has made investments in 2 other enterprises and holds 13 trademark registrations and 8 patents [1] - Additionally, it possesses 4 administrative licenses [1] Shareholders - The shareholders of Suzhou Xingao Tuowei Biotechnology Co., Ltd. include several investment partnerships and individuals, such as Suzhou Fuhuan Xingyi Venture Capital Partnership and Tianjin Fosun Haihe Medical Health Industry Fund Partnership [1]
苏州星奥拓维生物技术有限公司获“A轮”融资，金额近亿人民币
Sou Hu Cai Jing·2026-01-05 07:24